Exploitant Services in France for Pharmaceutical Companies
In France, the Exploitant role is a mandatory regulatory requirement for any pharmaceutical company wishing to commercialize a medicinal product via a marketing authorization. For pharmaceutical companies entering France, the Exploitant is the local structure that keeps products compliant on the French market. More than a French affiliate, it is a legal entity that secures compliant market access and protects patient safety.
Key takeaways:
- Exploitants are essential for foreign pharmaceutical companies that do not have a subsidiary in France to enter the market.
- Exploitants must obtain a pharmaceutical establishment license from the ANSM to operate in France.
- Azurbio Pharma France is an Exploitant and is the partner helping companies launch pharmaceutical products on the French market with confidence.
What is an Exploitant status in France?
In France, the Exploitant is the entity in charge of the exploitation of medicinal products once they are placed on the market. This Exploitant status is defined in the article R5124-2 of the French Public Health Code. It covers pharmaceutical activities such as distribution, advertising, medical information, pharmacovigilance, and post-approval follow-up.
Why does French law require it for pharmaceutical companies?
French authorities require one responsible establishment in France to oversee each product throughout its entire lifecycle, from market entry to ongoing monitoring. The goal is clear accountability, regulatory standards, and patient safety. For foreign pharmaceutical companies planning to launch a drug, the Exploitant is the only practical way to operate on the French market.
Regulatory compliance and ANSM approval
The Exploitant must hold an authorized pharmaceutical establishment status and maintain a complete Exploitant quality management system.. The Exploitant must ensure that all activities related to the product fully comply with French legislation throughout commercialization in France.
Pharmacovigilance and patient safety
Pharmacovigilance is a core Exploitant responsibility. It includes reporting adverse effects, safety assessment, coordination with the EU QPPV, and follow-up after marketing authorization. This responsibility is central to ensuring timely escalation. It is also critical in an early access program, where local oversight supports patients, authorities, and rapid action in France when needed.
Medical information and promotion
The Exploitant manages medical information requests, and interactions with healthcare professionals and patients… It is also responsible for reviewing and validating promotional and non-promotional materials to ensure the compliance with French regulatory requirements and presenting the product in a fair and non-misleading way. It also plays a key role in reviewing and validating both promotional and non-promotional materials, ensuring full compliance with French regulations while enabling clear, impactful, and trustworthy communication that supports the product’s successful positioning in the market.
Quality oversight, Distribution and supply integrity
Quality is central to the Exploitant role. The Exploitant oversees quality documentation, batch traceability, batch recall if required and manufacturer coordination, ensuring that only complaint medicines reach the market.
It also monitors distribution partners, and supports supply continuity.
Reimbursement and market access
Exploitant services can also support reimbursement strategy and dossiers submission to HAS. This support reduces launch friction and answers local cultural needs.
Why is this complex for international companies
Building an in-house Exploitant in France takes time, expertise, quality systems, and strong management. Companies need a Responsible Pharmacist, physical offices, documented management processes, permanent compliance control, and the ability to manage multiple products, authorities, and commercial needs at once.
How AzurBio supports companies
AzurBio offers Exploitant services as a local partner for pharmaceutical companies entering France. It can act as the licensed Exploitant or support an internal setup.
Our services cover regulatory compliance, pharmacovigilance, medical information, quality management, distribution oversight, authority interactions, and practical support tailored to client needs. They also cover key aspects of launch readiness and the setup of compliant local processes.
A practical route to the French market
With AzurBio, companies gain expertise, preparation, and a reliable partner able to take charge of critical responsibilities. This offer helps pharmaceutical companies accelerate approval, maintain quality, and keep products compliant while ensuring a secure route to the French market.
Start with a compliant launch plan
AzurBio supports the full route to market in France, from exploitation strategy to launch readiness. If your company needs compliant Exploitant services in France for pharmaceutical products, our team is ready to help.
